Cargando…

Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?

Colorectal cancer (CRC) originates as consequence of multiple genetic alterations. Some of the involved genes have been extensively studied (APC, TP53, KRAS, SMAD4, PIK3CA, MMR genes) in highly heterogeneous and poly-metastatic cohorts. However, about 10% of metastatic CRC patients presents with an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ottaiano, Alessandro, Santorsola, Mariachiara, Caraglia, Michele, Circelli, Luisa, Gigantino, Valerio, Botti, Gerardo, Nasti, Guglielmo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144733/ https://www.ncbi.nlm.nih.gov/pubmed/34034007 http://dx.doi.org/10.1016/j.tranon.2021.101131

Ejemplares similares

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Multifaceted Insights into Innovative Approaches to Treating Colorectal Cancer Metastasis: From Emerging Biological Factors to Radiomics
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The “Border-Time” Bias
por: Santorsola, Mariachiara, et al.
Publicado: (2022)

COVID-19 Outbreak: The North versus South Epidemiologic Italian Paradigm
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review
por: Santorsola, Mariachiara, et al.
Publicado: (2022)

Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients’ survival
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Genetic landscape of colorectal cancer patients manifesting tumor shrinkage during SARS-Cov-2 infection
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

The Tumor Dynamism Is the Dark Matter of the NGS Galaxy: How to Understand It?
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

p53: From Fundamental Biology to Clinical Applications in Cancer
por: Capuozzo, Maurizio, et al.
Publicado: (2022)

From Chaos to Opportunity: Decoding Cancer Heterogeneity for Enhanced Treatment Strategies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Characterization of KRAS Mutational Regression in Oligometastatic Patients
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
por: Capuozzo, Maurizio, et al.
Publicado: (2022)

Clinical and Molecular Characteristics of Rare Malignant Tumors of Colon and Rectum
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
por: Ottaiano, Alessandro, et al.
Publicado: (2013)

Circulating Vitamin D Level and Its Impact on Mortality and Recurrence in Stage III Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Circulating Tumor Cells as Predictive and Prognostic Biomarkers in Solid Tumors
por: Capuozzo, Maurizio, et al.
Publicado: (2023)

Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer
por: D’Alterio, Crescenzo, et al.
Publicado: (2020)

Genetic and biological hallmarks of colorectal cancer
por: Li, Jiexi, et al.
Publicado: (2021)

Malignant Sinonasal Tumors: Update on Histological and Clinical Management
por: Bracigliano, Alessandra, et al.
Publicado: (2021)

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial
por: Avallone, Antonio, et al.
Publicado: (2021)

Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms
por: Koenig, Alexander, et al.
Publicado: (2017)

The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer
por: De Palma, Fatima Domenica Elisa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u4nhsl4iiequibh6r6d4lh26tm